Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,358,195
  • Shares Outstanding, K 140,663
  • Annual Sales, $ 599,670 K
  • Annual Income, $ 273,740 K
  • 60-Month Beta 1.92
  • Price/Sales 10.37
  • Price/Cash Flow 18.88
  • Price/Book 5.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.87
  • Number of Estimates 9
  • High Estimate 1.31
  • Low Estimate 0.23
  • Prior Year 2.42
  • Growth Rate Est. (year over year) -64.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.25 +1.36%
on 01/27/20
64.34 -8.24%
on 01/09/20
-1.74 (-2.86%)
since 12/27/19
3-Month
53.98 +9.37%
on 10/28/19
66.22 -10.84%
on 12/16/19
+5.15 (+9.56%)
since 10/25/19
52-Week
53.34 +10.69%
on 10/24/19
86.58 -31.81%
on 04/08/19
+0.30 (+0.51%)
since 01/25/19

Most Recent Stories

More News
Watch for Ionis Pharmaceut to Potentially Pullback After Gaining 3.48% Yesterday

Ionis Pharmaceut (NASDAQ:IONS) traded in a range yesterday that spanned from a low of $61.03 to a high of $62.98. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high...

IONS : 59.08 (-0.57%)
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase...

AKCA : 18.43 (+1.82%)
IONS : 59.08 (-0.57%)
Huntington Disease Protein Market Trend, Future Demand and Forecast till 2025 | AFFiRiS AG, Ionis Pharmaceuticals, Inc., Neurimmune Holding AG, NLife Therapeutics, S.L.

The report offers detailed coverage of Huntington Disease Protein industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends,...

CADNF : 8.7400 (-0.35%)
CAS.TO : 11.55 (+0.35%)
IONS : 59.08 (-0.57%)
WRK : 40.30 (-1.56%)
DD : 57.79 (-2.69%)
APD : 234.88 (-3.72%)
LIN : 204.82 (-2.46%)
EPC : 26.81 (-1.14%)
SEE : 37.03 (+0.11%)
CAS : 0.41 (-18.00%)
ALB : 78.64 (-3.13%)
HXL : 73.78 (-0.59%)
Technological Advancements Expand Biopharmaceuticals' Production Capabilities

The biopharmaceutical industry is driven by multiple factors, all while rapidly evolving in the digital era. The need to engineer drugs to treat emerging diseases, an increase in the geriatric population...

NNVC : 13.01 (+53.96%)
GILD : 63.58 (+0.68%)
SRPT : 111.36 (-0.92%)
ABBV : 84.39 (+1.02%)
IONS : 59.08 (-0.57%)
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform...

AKCA : 18.43 (+1.82%)
IONS : 59.08 (-0.57%)
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development and commercial officer reporting...

IONS : 59.08 (-0.57%)
n-Lorem Foundation established to charitably provide antisense medicines to treat patients with ultra-rare diseases

The n-Lorem Foundation announced today its official launch as a nonprofit organization established to provide advanced, experimental RNA-targeted medicines free of charge for life to patients living with...

IONS : 59.08 (-0.57%)
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./

In the news release, Ionis' neurological franchise marks year of achievement, issued 07-Jan-2020 by Ionis Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the last bullet in the...

IONS : 59.08 (-0.57%)
Ionis' neurological franchise marks year of achievement

The neurological franchise of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, continued to shape the scientific and therapeutic landscape of the global biotechnology...

IONS : 59.08 (-0.57%)
Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 38th annual...

JPM : 132.65 (-0.38%)
IONS : 59.08 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade IONS with:

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Key Turning Points

2nd Resistance Point 61.72
1st Resistance Point 60.57
Last Price 59.12
1st Support Level 58.70
2nd Support Level 57.98

See More

52-Week High 86.58
Fibonacci 61.8% 73.88
Fibonacci 50% 69.96
Fibonacci 38.2% 66.04
Last Price 59.12
52-Week Low 53.34

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar